These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 23190347)

  • 21. Genotype Correlations With Blood Pressure and Efficacy From a Randomized Phase III Trial of Second-Line Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma.
    Escudier B; Rini BI; Motzer RJ; Tarazi J; Kim S; Huang X; Rosbrook B; English PA; Loomis AK; Williams JA
    Clin Genitourin Cancer; 2015 Aug; 13(4):328-337.e3. PubMed ID: 25816720
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.
    Rini BI; Wilding G; Hudes G; Stadler WM; Kim S; Tarazi J; Rosbrook B; Trask PC; Wood L; Dutcher JP
    J Clin Oncol; 2009 Sep; 27(27):4462-8. PubMed ID: 19652060
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Axitinib in the treatment of metastatic renal cell carcinoma.
    Ho TH; Jonasch E
    Future Oncol; 2011 Nov; 7(11):1247-53. PubMed ID: 22044199
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Five-year survival in patients with cytokine-refractory metastatic renal cell carcinoma treated with axitinib.
    Rini BI; de La Motte Rouge T; Harzstark AL; Michaelson MD; Liu G; Grünwald V; Ingrosso A; Tortorici MA; Bycott P; Kim S; Bloom J; Motzer RJ
    Clin Genitourin Cancer; 2013 Jun; 11(2):107-14. PubMed ID: 23391371
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma.
    Tomita Y; Uemura H; Fujimoto H; Kanayama HO; Shinohara N; Nakazawa H; Imai K; Umeyama Y; Ozono S; Naito S; Akaza H;
    Eur J Cancer; 2011 Nov; 47(17):2592-602. PubMed ID: 21889330
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-world dosing and drug costs with everolimus or axitinib as second targeted therapies for advanced renal cell carcinoma: a retrospective chart review in the US.
    Pal SK; Jonasch E; Signorovitch JE; Reichmann WM; Li N; Liu Z; Perez JR; Vogelzang NJ
    J Med Econ; 2016; 19(5):462-8. PubMed ID: 26652893
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Does axitinib (AG-01376) have a future role in metastatic renal cell carcinoma and other malignancies?
    Goldstein R; Pickering L; Larkin J
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1545-57. PubMed ID: 20942625
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma.
    Daimon M; Kato T; Kaino W; Takase K; Karasawa S; Wada K; Kameda W; Susa S; Oizumi T; Tomita Y; Kato T
    Jpn J Clin Oncol; 2012 Aug; 42(8):742-7. PubMed ID: 22628612
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comprehensive overview of axitinib development in solid malignancies: focus on metastatic renal cell carcinoma.
    Carmichael C; Lau C; Josephson DY; Pal SK
    Clin Adv Hematol Oncol; 2012 May; 10(5):307-14. PubMed ID: 22706540
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Axitinib for the treatment of metastatic renal cell carcinoma.
    Parekh H; Griswold J; Rini B
    Future Oncol; 2016 Feb; 12(3):303-11. PubMed ID: 26769075
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Individualized dosing with axitinib: rationale and practical guidance.
    Schmidinger M; Danesi R; Jones R; McDermott R; Pyle L; Rini B; Négrier S
    Future Oncol; 2018 Apr; 14(9):861-875. PubMed ID: 29264944
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study.
    Rixe O; Bukowski RM; Michaelson MD; Wilding G; Hudes GR; Bolte O; Motzer RJ; Bycott P; Liau KF; Freddo J; Trask PC; Kim S; Rini BI
    Lancet Oncol; 2007 Nov; 8(11):975-84. PubMed ID: 17959415
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Axitinib in metastatic renal cell carcinoma: beyond the second-line setting.
    Umeyama Y; Shibasaki Y; Akaza H
    Future Oncol; 2017 Sep; 13(21):1839-1852. PubMed ID: 28707479
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial.
    Rini BI; Quinn DI; Baum M; Wood LS; Tarazi J; Rosbrook B; Arruda LS; Cisar L; Roberts WG; Kim S; Motzer RJ
    Target Oncol; 2015 Mar; 10(1):45-53. PubMed ID: 24595903
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis.
    Fischer A; Wu S; Ho AL; Lacouture ME
    Invest New Drugs; 2013 Jun; 31(3):787-97. PubMed ID: 23345001
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incidence and risk of hypertension with a novel multi-targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta-analysis.
    Qi WX; He AN; Shen Z; Yao Y
    Br J Clin Pharmacol; 2013 Sep; 76(3):348-57. PubMed ID: 23617405
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The European Medicines Agency approval of axitinib (Inlyta) for the treatment of advanced renal cell carcinoma after failure of prior treatment with sunitinib or a cytokine: summary of the scientific assessment of the committee for medicinal products for human use.
    Tzogani K; Skibeli V; Westgaard I; Dalhus M; Thoresen H; Slot KB; Damkier P; Hofland K; Borregaard J; Ersbøll J; Salmonson T; Pieters R; Sylvester R; Mickisch G; Bergh J; Pignatti F
    Oncologist; 2015 Feb; 20(2):196-201. PubMed ID: 25616431
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of Renal Impairment on the Pharmacokinetics and Safety of Axitinib.
    Chen Y; Rini BI; Motzer RJ; Dutcher JP; Rixe O; Wilding G; Stadler WM; Tarazi J; Garrett M; Pithavala YK
    Target Oncol; 2016 Apr; 11(2):229-34. PubMed ID: 26400730
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Axitinib dose titration: analyses of exposure, blood pressure and clinical response from a randomized phase II study in metastatic renal cell carcinoma.
    Rini BI; Melichar B; Fishman MN; Oya M; Pithavala YK; Chen Y; Bair AH; Grünwald V
    Ann Oncol; 2015 Jul; 26(7):1372-7. PubMed ID: 25701454
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Axitinib: from preclinical development to future clinical perspectives in renal cell carcinoma.
    Zakharia Y; Zakharia K; Rixe O
    Expert Opin Drug Discov; 2015; 10(8):925-35. PubMed ID: 26039031
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.